KR20190045354A - 티로신 키나아제 저해제 및 이의 응용 - Google Patents

티로신 키나아제 저해제 및 이의 응용 Download PDF

Info

Publication number
KR20190045354A
KR20190045354A KR1020197010451A KR20197010451A KR20190045354A KR 20190045354 A KR20190045354 A KR 20190045354A KR 1020197010451 A KR1020197010451 A KR 1020197010451A KR 20197010451 A KR20197010451 A KR 20197010451A KR 20190045354 A KR20190045354 A KR 20190045354A
Authority
KR
South Korea
Prior art keywords
group
compound
mmol
washed
dryness
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197010451A
Other languages
English (en)
Korean (ko)
Inventor
팡 순
요우니 짠
Original Assignee
상하이 샹진 바이오테크놀로지 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 상하이 샹진 바이오테크놀로지 컴퍼니 리미티드 filed Critical 상하이 샹진 바이오테크놀로지 컴퍼니 리미티드
Priority to KR1020217037589A priority Critical patent/KR102382039B1/ko
Publication of KR20190045354A publication Critical patent/KR20190045354A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020197010451A 2016-09-13 2017-06-22 티로신 키나아제 저해제 및 이의 응용 Ceased KR20190045354A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217037589A KR102382039B1 (ko) 2016-09-13 2017-06-22 티로신 키나아제 저해제 및 이의 응용

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610822529.0 2016-09-13
CN201610822529.0A CN107235896B (zh) 2016-09-13 2016-09-13 酪氨酸激酶抑制剂及其应用
PCT/CN2017/089501 WO2018049861A1 (zh) 2016-09-13 2017-06-22 酪氨酸激酶抑制剂及其应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217037589A Division KR102382039B1 (ko) 2016-09-13 2017-06-22 티로신 키나아제 저해제 및 이의 응용

Publications (1)

Publication Number Publication Date
KR20190045354A true KR20190045354A (ko) 2019-05-02

Family

ID=59982910

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197010451A Ceased KR20190045354A (ko) 2016-09-13 2017-06-22 티로신 키나아제 저해제 및 이의 응용
KR1020217037589A Active KR102382039B1 (ko) 2016-09-13 2017-06-22 티로신 키나아제 저해제 및 이의 응용

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217037589A Active KR102382039B1 (ko) 2016-09-13 2017-06-22 티로신 키나아제 저해제 및 이의 응용

Country Status (8)

Country Link
US (1) US10882853B2 (cg-RX-API-DMAC10.html)
EP (1) EP3511327B1 (cg-RX-API-DMAC10.html)
JP (1) JP7487921B2 (cg-RX-API-DMAC10.html)
KR (2) KR20190045354A (cg-RX-API-DMAC10.html)
CN (2) CN110437145A (cg-RX-API-DMAC10.html)
AU (1) AU2017325641B2 (cg-RX-API-DMAC10.html)
ES (1) ES2902549T3 (cg-RX-API-DMAC10.html)
WO (1) WO2018049861A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3655406A1 (en) 2017-07-18 2020-05-27 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyridine-derivatives
SG11202006945PA (en) 2018-01-26 2020-08-28 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
AU2019212800B2 (en) 2018-01-26 2024-05-23 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
HRP20251184T1 (hr) * 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
AR119069A1 (es) * 2019-06-04 2021-11-24 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de quinasas
CN112358469A (zh) * 2020-03-18 2021-02-12 北京康辰药业股份有限公司 血管生成抑制剂、其制备方法及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210607B1 (en) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
UY31800A (es) * 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
AU2009303602B2 (en) * 2008-10-14 2012-06-14 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
EP2408300B1 (en) * 2009-03-21 2016-05-11 Sunshine Lake Pharma Co., Ltd. Amino ester derivatives, salts thereof and methods of use
US8664244B2 (en) 2010-09-12 2014-03-04 Advenchen Pharmaceuticals, LLC Compounds as c-Met kinase inhibitors
CN105884695B (zh) * 2015-02-13 2019-02-26 山东轩竹医药科技有限公司 杂环衍生物类酪氨酸激酶抑制剂
CN104817497B (zh) * 2015-03-20 2017-03-08 南京众睿缘生物科技有限公司 一种炔代喹啉衍生物及其制备方法和用途
CN105017163A (zh) * 2015-08-25 2015-11-04 佛山市赛维斯医药科技有限公司 双乙氧基苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及其用途
CN105218445B (zh) * 2015-08-25 2018-05-22 江苏中邦制药有限公司 一种酪氨酸激酶抑制剂Foretinib的制备方法
CN105085416A (zh) * 2015-08-25 2015-11-25 佛山市赛维斯医药科技有限公司 一类硝基取代的双烷氧苯并喹唑啉类酪氨酸激酶抑制剂及用途
CN105001168A (zh) * 2015-08-25 2015-10-28 佛山市赛维斯医药科技有限公司 三烷氧基取代的苯并喹唑啉类酪氨酸激酶抑制剂及其用途

Also Published As

Publication number Publication date
KR102382039B1 (ko) 2022-04-01
US10882853B2 (en) 2021-01-05
ES2902549T3 (es) 2022-03-28
EP3511327A4 (en) 2019-08-07
EP3511327B1 (en) 2021-10-27
WO2018049861A1 (zh) 2018-03-22
EP3511327A1 (en) 2019-07-17
CN107235896B (zh) 2019-11-05
US20190248772A1 (en) 2019-08-15
JP7487921B2 (ja) 2024-05-21
CN110437145A (zh) 2019-11-12
CN107235896A (zh) 2017-10-10
AU2017325641A1 (en) 2019-04-11
AU2017325641B2 (en) 2021-08-26
KR20210143935A (ko) 2021-11-29
JP2019529435A (ja) 2019-10-17

Similar Documents

Publication Publication Date Title
KR102382039B1 (ko) 티로신 키나아제 저해제 및 이의 응용
KR102470598B1 (ko) 메틸/플루오로-피리디닐-메톡시 치환된 피리디논-피리디닐 화합물 및 플루오로-피리미디닐-메톡시 치환된 피리디논-피리디닐 화합물
CN106220635B (zh) 作为parp抑制剂的稠合的四环或五环的二氢二氮杂*并咔唑酮
KR101971387B1 (ko) Ask1 억제제의 고체 형태
EP2312950B1 (en) Compounds as kinase inhibitors
KR20250073451A (ko) 신형 prmt5 억제제 및 그 응용
CN107735399A (zh) 作为蛋白质激酶的调节剂的手性二芳基大环
WO2003026665A1 (en) 2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
JP2023536634A (ja) 自己免疫疾患および癌の処置のための小分子
EA029771B1 (ru) Химические соединения
JP7641965B2 (ja) 疾患処置に使用するための大環状分子
CN109776607B (zh) 芳基磷氧类和芳基磷硫类化合物及其制备方法和应用
CN111093658A (zh) 用于治疗皮肤疾病的稠合杂芳环-苯胺化合物
Chen et al. O‐Linked Triazolotriazines: Potent and Selective c‐Met Inhibitors
CN120271607A (zh) Ras抑制剂
CN102746241B (zh) 2,3,5-三取代苯甲酰胺类化合物及其制备方法和用途
CN107235897B (zh) 酪氨酸激酶抑制剂及其应用
TW202604504A (zh) 含氮並環化合物、含其的藥物組合物及其應用
JP6541635B2 (ja) Parp阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン
CN122059877A (zh) 一种萘酰胺类化合物、其制备方法及其应用
CN118255714A (zh) 受体酪氨酸激酶抑制剂、其制备方法及其应用
CN116490507A (zh) 用于治疗癌症的杂环包缩合cdc7激酶抑制剂

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20190411

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20200603

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200903

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210520

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200903

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20210520

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20210104

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20210818

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20210719

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20210520

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20210104

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20200903

X601 Decision of rejection after re-examination
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20211112

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20210818

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20210520

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20220721

Appeal identifier: 2021101002889

Request date: 20211112

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20211117

J301 Trial decision

Free format text: TRIAL NUMBER: 2021101002889; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20211112

Effective date: 20220721

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20220721

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20211112

Decision date: 20220721

Appeal identifier: 2021101002889

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)